vs

Side-by-side financial comparison of BayFirst Financial Corp. (BAFN) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

BayFirst Financial Corp. is the larger business by last-quarter revenue ($10.3M vs $6.6M, roughly 1.6× Lineage Cell Therapeutics, Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -55.0%, a 67.8% gap on every dollar of revenue. Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs -29.6%).

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

BAFN vs LCTX — Head-to-Head

Bigger by revenue
BAFN
BAFN
1.6× larger
BAFN
$10.3M
$6.6M
LCTX
Higher net margin
LCTX
LCTX
67.8% more per $
LCTX
12.9%
-55.0%
BAFN
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
-29.6%
BAFN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BAFN
BAFN
LCTX
LCTX
Revenue
$10.3M
$6.6M
Net Profit
$-5.7M
$851.0K
Gross Margin
Operating Margin
-99.1%
Net Margin
-55.0%
12.9%
Revenue YoY
130.4%
Net Profit YoY
-130.6%
126.0%
EPS (diluted)
$-1.48
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAFN
BAFN
LCTX
LCTX
Q1 26
$10.3M
Q4 25
$11.2M
$6.6M
Q3 25
$10.2M
$3.7M
Q2 25
$23.1M
$2.8M
Q1 25
$19.8M
$1.5M
Q4 24
$32.9M
$2.9M
Q3 24
$21.7M
$3.8M
Q2 24
$20.8M
$1.4M
Net Profit
BAFN
BAFN
LCTX
LCTX
Q1 26
$-5.7M
Q4 25
$-2.5M
$851.0K
Q3 25
$-18.9M
$-29.8M
Q2 25
$-1.2M
$-30.5M
Q1 25
$-335.0K
$-4.1M
Q4 24
$9.8M
$-3.3M
Q3 24
$1.1M
$-3.0M
Q2 24
$866.0K
$-5.8M
Gross Margin
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Operating Margin
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
-25.3%
-99.1%
Q3 25
-253.0%
-102.9%
Q2 25
-7.1%
-715.4%
Q1 25
-2.3%
-433.1%
Q4 24
-178.2%
Q3 24
7.1%
-101.6%
Q2 24
5.9%
-416.7%
Net Margin
BAFN
BAFN
LCTX
LCTX
Q1 26
-55.0%
Q4 25
-22.1%
12.9%
Q3 25
-184.7%
-809.0%
Q2 25
-5.3%
-1101.8%
Q1 25
-1.7%
-275.6%
Q4 24
91.8%
-114.1%
Q3 24
5.2%
-80.3%
Q2 24
4.2%
-409.1%
EPS (diluted)
BAFN
BAFN
LCTX
LCTX
Q1 26
$-1.48
Q4 25
$-0.71
$0.00
Q3 25
$-4.66
$-0.13
Q2 25
$-0.39
$-0.13
Q1 25
$-0.17
$-0.02
Q4 24
$2.21
$0.00
Q3 24
$0.18
$-0.02
Q2 24
$0.12
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAFN
BAFN
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$134.5M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$81.9M
$44.5M
Total Assets
$1.2B
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAFN
BAFN
LCTX
LCTX
Q1 26
$134.5M
Q4 25
$207.0M
$55.8M
Q3 25
$118.5M
$40.5M
Q2 25
$77.3M
$42.3M
Q1 25
$63.2M
$47.9M
Q4 24
$77.8M
$47.8M
Q3 24
$64.4M
$32.7M
Q2 24
$60.8M
$38.5M
Stockholders' Equity
BAFN
BAFN
LCTX
LCTX
Q1 26
$81.9M
Q4 25
$87.6M
$44.5M
Q3 25
$89.7M
$22.0M
Q2 25
$108.2M
$48.4M
Q1 25
$110.1M
$79.0M
Q4 24
$110.9M
$78.4M
Q3 24
$102.3M
$66.2M
Q2 24
$101.0M
$68.3M
Total Assets
BAFN
BAFN
LCTX
LCTX
Q1 26
$1.2B
Q4 25
$1.3B
$112.6M
Q3 25
$1.3B
$89.6M
Q2 25
$1.3B
$90.8M
Q1 25
$1.3B
$111.8M
Q4 24
$1.3B
$113.2M
Q3 24
$1.2B
$96.6M
Q2 24
$1.2B
$102.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAFN
BAFN
LCTX
LCTX
Operating Cash FlowLast quarter
$-4.9M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-79.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
$285.3M
$-4.9M
Q3 25
$47.3M
$-3.6M
Q2 25
$63.3M
$-5.5M
Q1 25
$74.2M
$-4.9M
Q4 24
$390.5M
$-6.3M
Q3 24
$90.8M
$-5.8M
Q2 24
$78.8M
$-5.2M
Free Cash Flow
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
$285.0M
$-5.3M
Q3 25
$47.3M
$-3.6M
Q2 25
$63.1M
$-5.6M
Q1 25
$74.1M
$-5.0M
Q4 24
$388.8M
$-6.7M
Q3 24
$90.5M
$-5.9M
Q2 24
$78.4M
$-5.2M
FCF Margin
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
2554.2%
-79.9%
Q3 25
462.2%
-98.6%
Q2 25
272.7%
-200.8%
Q1 25
375.1%
-331.8%
Q4 24
1180.9%
-234.0%
Q3 24
416.5%
-156.1%
Q2 24
376.1%
-371.2%
Capex Intensity
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
2.7%
6.0%
Q3 25
0.1%
0.3%
Q2 25
0.8%
0.5%
Q1 25
0.4%
6.5%
Q4 24
5.1%
12.7%
Q3 24
1.5%
3.0%
Q2 24
1.9%
3.6%
Cash Conversion
BAFN
BAFN
LCTX
LCTX
Q1 26
Q4 25
-5.73×
Q3 25
Q2 25
Q1 25
Q4 24
39.95×
Q3 24
79.85×
Q2 24
90.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BAFN
BAFN

Net Interest Income$9.4M91%
Noninterest Income$884.0K9%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons